Wire · operational-macro
TALAPRO-3 Results and FDA Approval of Talazoparib plus Enzalutamide in HRR-Altered mHSPC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 November 2026 · Fusion42 review
The TALAPRO-3 trial showed a 52% reduction in progression or death risk with talazoparib plus enzalutamide in HRR-altered metastatic hormone-sensitive prostate cancer. The FDA has approved this combination treatment demonstrating durable progression-free survival despite notable anemia side effects managed by dose reductions.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your prostate cancer treatment options just expanded with a newly FDA-approved combo of talazoparib and enzalutamide for specific genetic cases. This approval creates a clear path to develop or prioritise precision medicine solutions around HRR-altered metastatic prostate cancer.
◆ Coverage
1 source · 13 Nov 2026
◆ Related on Wire
◆ Topics